AmeriSourceBergen Adds New Distribution Center in Australia

Article

PTSM: Pharmaceutical Technology Sourcing and Management

PTSM: Pharmaceutical Technology Sourcing and ManagementPTSM: Pharmaceutical Technology Sourcing and Management-03-04-2015
Volume 11
Issue 3

The new center represents AmerisourceBergen’s first facility erected specifically for clinical trial and commercial third-party logistics activities.


AmerisourceBergen’s specialty logistics company World Courier announced on Feb. 11, 2015 that the company opened a new global distribution center in Melbourne, Australia. The new location will serve existing World Courier clinical trial clients as well as global manufacturers seeking to commercialize products in Australia.

The new facility will enable expanded patient access to time- and temperature-sensitive medications and will expand World Courier’s global reach, according to a release. World Courier has already “successfully piloted commercial 3PL in Australia” at another facility, according to John Butler, president of World Courier, and it is now capable of launching a nationwide effort through its collaboration with AmerisourceBergen.

“We’re taking World Courier’s local market knowledge and specialty logistics expertise and combining it with the supply chain and commercialization experience that AmerisourceBergen is renowned for in North America,” said Doug Cook, president of Global Specialty Logistics at AmerisourceBergen, in a statement. Since AmerisourceBergen purchased World Courier in 2012 for $520 million in cash, the companies have been working together to merge their collective talents, he added.

A statement from AmerisourceBergen in 2012 released shortly after the completion of the World Courier acquisition noted that the addition of World Courier’s capabilities would give AmerisourceBergen a “platform for the introduction of [their] specialty services outside North America.”

Source:
AmerisourceBergen

Recent Videos
Behind the Headlines episode 6
CPHI Milan 2024: Highlighting the Benefits of Integrated Services
Behind the Headlines episode 5
Buy, Sell, Hold: Cell and Gene Therapy
Buy, Sell, Hold: Cell and Gene Therapy
Buy, Sell, Hold: Cell and Gene Therapy
Related Content